| Grandi T, Sparatore F, Gnerre C, Crivori P, Carrupt PA, Testa B.
Monoamine Oxidase Inhibitor Properties of Some Benzazoles: Structure-activity Relationships.
AAPS PharmSci.
1999;
1
(4): article
16.
DOI:
10.1208/ps010416
| Teresa Grandi,1
Fabio Sparatore,1
Carmela Gnerre,2
Patrizia Crivori,2
Pierre-Alain Carrupt,2
and Bernard Testa2
1Department of Pharmaceutical Sciences, Faculty of Pharmacy, Viale Benedetto XV, 3, I-16132 Genova, Italy 2Institute of Medicinal Chemistry, School of Pharmacy, BEP, University of Lausanne, CH-1015 Lausanne-Dorigny, Switzerland
Correspondence to: Bernard Testa Tel: +41-21-692 4521 Fax: +41-21-692 4525 Email: bernard.testa@ict.unil.ch | Submitted: September 28, 1999; Accepted: October 8, 1999; Published: October 24, 1999 | Keywords:
Benzazoles, MAO-B, MAO-B | Benzazoles containing two or three nitrogen atoms were screened
for their inhibitory activity toward monoamine oxidases MAO-A and MAO-B. In
order to clarify the mechanism of interaction of these compounds with the
enzyme, their electronic structure was calculated at the ab initio level and the
influence of lipophilicity on activity was investigated. The mode of binding of
benzazoles to MAO-B appears different from that of previously investigated
heterocycles.  |
Monoamine oxidase (MAO) is a FAD-containing enzyme of the outer
mitochondrial membrane1 existing as two isoenzymes
(MAO-A and MAO-B) that differ in their substrate specificity and sensitivity to
inhibitors.2 Recently, 7-nitroindazole (7-NI), a potent inhibitor of nitric
oxide synthase, was also found to be an MAO-B inhibitor.3 Taking into account the structural features of 7-NI and the extensive literature showing that a wide variety of planar, heterocyclic
systems are competitive inhibitors of MAO,4 the
reversible MAO-A and MAO-B inhibitory activity of benzazoles was investigated Table 1. Lipophilicity was measured in two solvent systems (n-octanol/water and 1,2-dichloroethane/water). Hydrogen bonding properties were deduced and are
discussed in relation to biological activity. Ab initio molecular orbital
calculations and molecular electrostatic potentials (MEP) were used to interpret
and rationalize the data.
 | The substituted benzotriazoles, benzimidazoles, and indazoles
were purchased from Aldrich (Buchs, Switzerland) or prepared according to known
procedures.5,6 The identity and
purity of all synthesized compounds were checked by 1H-NMR, IR and
elemental analyses. Kynuramine was obtained from Sigma Chemical Co. (St. Louis,
MO, USA). The in vitro MAO inhibitory activities were studied using a
crude rat brain mitochondrial suspension.7 This
suspension, which was set to a final concentration of 1.0 mg/ml, was
preincubated at 37°C for 5 minutes with either clorgyline (irreversible MAO-A
inhibitor) or (-)-deprenyl (irreversible MAO-B inhibitor) at a concentration of
250 nM. The potential inhibitor under study was then added and further incubated
for 5 minutes. Finally the nonselective substrate kynuramine was added to a
concentration equal to its Km (90 µM for MAO-A and 60 µM for MAO-B). The
formation of its metabolite (4-hydroxyquinoline) was monitored at 314 nm using a
Kontron UVIKON 941 spectrophotometer. IC50 values were calculated
from a hyperbolic equation as reported previously.8 Potentiometric titrations of ionizable compounds were performed
with the PCA 101 Apparatus (Sirius Analytical Instruments, Forrest Row, East
Sussex, UK) equipped with a semi-micro Ross-type double junction combination pH
electrode (Orion 8103SC), a temperature probe, an overhead stirrer, a precision
dispenser, and a six-way valve for distributing reagents and titrants
(0.5 M HCl, 0.5 M KOH, 0.15 M KCl, and MeOH). Shake-flask
measurements were performed according to the method described in.9 Calculated log P (ClogP) were obtained with the
MedChem program.10 Quantum mechanical calculations
were performed using the software Spartan 5.0 running on a Silicon Graphics
Origin 2000 workstation. The geometries were fully optimized using the 3-21G
basis set for ab initio calculations and standard convergence
criteria.  | Partitioning and intramolecular interactions Lipophilicity was measured in two biphasic isotropic systems,
namely n-octanol/water and 1,2-dichloroethane (1,2-dce)/water. The
correlation between the log Poct and the ClogP values was good
(n =18, r2 = 0.94, s = 0.15, F = 252)
indicating that the intramolecular effects operating in n-octanol/water
were similar for the three series of compounds. However, the behavior of the
three series was different in 1,2-dce/water as illustrated by their
Δlog Poct-dce values. Because Δlog Poct-dce
measures the H-bonding capacity of a solute (mainly of its H-bonding donor
capacity),11,12 the results
suggest that the benzimidazoles 2a, 2b, and 2d-f
(Δlog Poct-dce about 1.5) and the benzotriazoles 3a,
3b, and 3d-g (Δlog Poct-dce about 1.2) are better
H-bond donors than the corresponding indazoles 1a-f
(Δlog Poct-dce about 0.5). However, variations in other
properties (dipole moment, polarizability) may also operate. The comparison between partition coefficients also reveals the
existence of a strong intramolecular H-bond between the nitro substituent and
the N1-H function, responsible for the small Δlog Poct-dce of 1d, 2c, and 3c. As already described for o-nitrophenols,12 this intramolecular H-bond
is stronger in 1,2-dce/water. Structure-activity relationships The IC50 values of the tested compounds are reported
in Table 1. Inspection of the table clearly reveals that the compounds were moderate or weak inhibitors of MAO-B, with little or no activity toward MAO-A. The values
are in the range from 2.8 µM to >100 µM for MAO-B, and from 40 µM to >100
µM for MAO-A. The inhibitors seem to act in a reversible and time-independent
manner, with a moderate selectivity toward MAO-B for the most active
compounds. Because MAO-A inhibition was low and presented insufficient
variation, structure-;activity relationships could only be examined for MAO-B
inhibition. As discussed below, only qualitative trends are apparent due to the
limited structural variation of the compounds examined in this exploratory
work. No trends and no relations were found between lipophilicity
descriptors (log Poct or log Pdce) and activity.
In contrast with other results,13 lipophilicity was
not a discriminant factor in these series, suggesting that the stereoelectronic
characteristics of the heterocycles must be the major modulator of
activity. As already described,14 charge
transfer interactions between the FAD cofactor and inhibitors may contribute to
MAO inhibition. Electronic properties (the energy and shape of the frontier
molecular orbitals) were examined by ab initio calculations (results not shown).
No clear relation between MAO-B inhibition, differences in topology, and the
energy of the frontier orbitals was found, suggesting that charge transfer
interactions, if they exist, cannot explain variations in activity. Figure 1.
Indazoles were the most active compounds; benzotriazoles
retained some inhibition potency; and benzimidazoles were mostly inactive. Thus,
activity appears linked to the endocyclic topology in which nitrogens in
position 1, 2, and 3 may act as proton donor (N1) or acceptor
(N2 and N3). 5-Nitro- and 6-nitroindazoles (IC50 about 3 µM for
1b and 1c) emerge as the most active MAO-B inhibitors. Moreover,
the activity of the 7-nitro-substituted derivatives 1d, 2c, and
3c having a strong intramolecular H-bond was lowered, suggesting that an
H-bond between the NH function and the enzyme is required for inhibition.
Recently, Wouters et al.13 presented
a common pharmacophore for the binding of heterocyclic MAO-B inhibitors. They
proposed a primary binding site characterized by three H-bond acceptor anchor
points and a secondary lipophilic binding site. The heterocyclic compounds
examined here do not fit this general pharmacophore. Indeed, they differ in the
distance between the lipophilic and heterocylic moieties and in the presence of
an H-bond donor N-H function. However, this function cannot be the only factor
determining activity since the benzimidazoles and the triazoles were less active
despite their higher H-bonding donor capacity. The three nitrogen atoms elicit favorable or unfavorable
interaction with the active site of the enzyme. Benzimidazole derivatives were
completely inactive, except compounds 2b and 2c, in which the
nitro group modifies the electronic features of the heterocycle leading to a
weak activity toward MAO-B. This implies that the absence of N2
and/or the presence of N3 as H-bond acceptors are detrimental to
activity. Indeed, benzotriazoles retained some activity, suggesting that
N2 is in interaction with the enzyme and counterbalances the
unfavorable presence of N3. The three series of heterocycles display a different
distribution of MEP. Only the regions around the heterocyclic nitrogens were
found to be informative. They are represented in Figure 2 for the unsubstituted derivatives 1a, 2a, and 3a. Close to the N1-H function, a positive region is generated by the H-atom, which can be related to the H-bond donating capacity of this function.
In the indazoles (1a-;1f), the positive potential was smaller than that
in the corresponding benzimidazoles (2a-;2f) and benzotriazoles
(3a-;3g), a result in line with the smaller Δlog Poct-dce
values.
An electron withdrawing substituent (NO2 or Cl) in
the 5 or 6 position enhanced the positive electrostatic potential leading to
more active compounds, whereas the formation of an intramolecular H-bond with
the 7-NO2 substituent gave a lower potential and less active
compounds. The lone pair of the N2 and N3 atoms
produced a negative potential whose intensity changed with the nature of the
heterocycle and its substituents. The present results thus suggest that, the
negative zone of N2 in indazoles and benzotriazoles allowed an
additional interaction with an H-bond donor group in the enzyme, the lower
activity of benzimidazoles and benzotriazoles was caused by the presence of a
strongly negative region near the N3 atom. In conclusion, three features appear to influence MAO-B
inhibition. These features may be related to an optimal binding mode allowing a
good interaction between the ligand and the FAD cofactor in MAO-B. First, the H-bond donor capacity near N1-H influenced
activity. When the H-bond donor capacity was lower, activity was lower (e.g.,
for 1d, 2c, and 3c). The presence of this anchor point is
original with respect to previously investigated heterocycles, suggesting that
these compounds may adopt a different mode of binding in the catalytic pocket of
MAO-B. The second feature is the presence of a negative region near the
N2 atom that offers an additional anchor point. This second binding
site may be the one proposed by Wouters et al. in their pharmacophore.13 The presence of a negative region near the N3 atom
lowered activity, suggesting that a high polarity in this region had a repulsive
influence. 
| These relations lead us to propose an original pharmacophore for
MAO-B inhibition (Figure 3), with the ring substituents modulating the electrostatic potential of both the positive and the negative region, and hence activity. Such results
offer a promising starting point to design more potent MAO-B inhibitors with a
binding pattern different from that of known inhibitors.

| The authors are indebted to the Italian MURST and to the Swiss
National Science Foundation for financial support. 
|
1.
Shih JC. Molecular basis of human MAO
A and B. Neuropsychopharm. 1991;4:1-7. PubMed
2.
Gargalidis-Moudanos C, Remaury A,
Parini A. Predominant expression of monoamine oxidase B isoform in rabbit renal
proximal tube: regulation by I2 imidazoline ligands in intact cells. Mol Pharmacol. 1997;51:637-643. PubMed
3.
Castagnoli K, Palmer S, Anderson A,
Bueters T, Castagnoli Jr. N. The neuronal nitric oxide synthase inhibitor
7-nitroindazole also inhibits the monoamine oxidase-B-catalyzed oxidation of
1-methyl-4-phenyl-1 , 2 ,3 , 6-tetrahydropyridine. Chem Res Toxicol. 1997;10:364-368. PubMed
4.
Thull U, Testa B. Screening of
unsubstituted cyclic compounds as inhibitors of monoamine oxidases. Biochem Pharmacol. 1994;47:2307-2310. PubMed
5.
Paglietti G, Sparatore F.
Preparazione di acidi b-benzotriazolilbutirrici variamente sostituiti quali
potenziali coleretici. Farmaco. 1972;27:380-396. PubMed
6.
Crowther AF, Curd FHS, Davey DG, Stacey GJ. Synthetic antimalarials. Part XXXIX. Sialkylaminoalkylaminoquinolines. J Chem Soc. 1949;1260-1271.
7.
Weissbach H, Smith TE, Daly JW,
Witkop B, Udenfriend S. A rapid spectrophotometric assay of monoamine oxidase
based on the rate of disappearance of kynuramine. J Biol Chem. 1960;235:1160-1163. PubMed
8.
Thull U, Kneubühler S, Testa B,
Borges MFM, Pinto MMM. Substituted xanthones as selective and reversible
monoamine oxidase A (MAO-A) inhibitors. Pharm Res. 1993;10:1187-1190. PubMed
9.
Dearden JC, Bresnen GM. The
measurement of partition coefficients. Quant. Struct-Act Relat. 1988;7:133-144. PubMed
10.
DAYLIGHT Software 4.41, Daylight
Chemical Information System, Inc., Irvine, California: 1995.
11.
Wouters J, Ooms F, Jegham S, Koenig
JJ, George P, Durant F. Reversible inhibition of type B monoamine oxidase.
Theoretical study of model diazo heterocyclic compounds. Eur J Med Chem. 1997;32:721-730. PubMed
12.
Steyaert G, Lisa G, Gaillard P,
Boss G, Reymond F, Girault HH, Carrupt PA, Testa B. Intermolecular forces
expressed in 1,2-dichloroethane/water partition coefficient: a solvatochromic
analysis. J Chem Soc. 1997;93:401-406. PubMed
13.
Chopineaux-Courtois V, Reymond F,
Bouchard G, Carrupt PA, Testa B, Girault HH. Effects of charge and of
intramolecular structure on the lipophilicity of nitrophenols. J Am Chem Soc. 1999;121:1743-1747. PubMed
14.
Wouters J, Durant F, Champagne B,
André JM. Electronic properties of flavins: implications on the reactivity and
absorption properties of flavoproteins. Int J Quant Chem. 1997;64:721-733. PubMed

|
|